Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic.
The dopamine hypothesis suggests that dopamine abnormalities underlie psychosis, irrespective of diagnosis, implicating dopamine dysregulation in bipolar affective disorder and schizophrenia...
Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.
This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone.
The aim of this clinical trial was to obtain proof of concept for high-dose pyridoxamine as a novel treatment for schizophrenia with enhanced carbonyl stress.
Brexpiprazole (Rxulti, Rexulti) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in some other countries, including Japan.
Sunovion Pharmaceuticals has announced that the FDA has approved the supplemental New Drug Application (sNDA) for Latuda (lurasidone HCI) for...
Gedeon Richter Plc. announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic...